MHRN III Projects

Buprenorphine Supplement

Funder: NIMH

Grant Number: U19MH121738-02S2  (supplement to main MHRN cooperative agreement)

Grant period: 9/17/2020 – 8/31/2022

Brief Narrative: This large observational study will evaluate the effects of initiating buprenorphine treatment on subsequent suicidal behavior among people with opioid use disorder, including those with and without co-occurring mental health conditions or other known risk factors for suicidal behavior. We will use comprehensive health records data from four large health systems serving a combined member/patient population of approximately 11 million. Analyses will examine the overall effect of buprenorphine treatment on subsequent suicide attempts or death, heterogeneity of effects in patient subgroups, and specificity of effects to buprenorphine vs other medications.

Lead Site: KPWA

Zero Suicide

Brief Narrative:

MHRN III Admin Core

MHRN III Methods Core

SP1 Perinatal

Pilot 1